A combination therapy using IL-12 and soluble IL-4 receptor on herpes simplex virus type 1 infection in a human-SCID chimera model of thermal injury

Tatsushi Katakura, Makiko Kobayashi, Kazuhiko Fujita, David Herndon, Richard B. Pollard, Fujio Suzuki

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Herpes simplex virus type 1 (HSV-1) is a severe pathogen in thermally injured patients. Type 1 T cells are essential for the host's anti-HSV protective immunity. Type 2 cytokines, commonly detected in thermally injured patients, have been described as inhibitors for the type 1 T cell generation. Therefore, the antiviral effects of combination therapy with a type 1 T cell inducer [interleukin (IL)-12] and a type 2 T cell inhibitor [soluble IL-4 receptor (sIL-4R)] were investigated in severe combined immunodeficiency (SCID) mice inoculated with peripheral blood lymphocytes (PBL) of thermally injured patients. Patient PBL-SCID chimeras (SCID mice inoculated with patient PBL) were susceptible to infection with 1 × 103 PFU/kg of HSV-1 (0% survival), while healthy PBL-SCID chimeras (SCID mice inoculated with PBL from healthy donors) were resistant (92% survival). When patient PBL-SCID chimeras exposed to HSV-1 were treated with saline, human recombinant (r) IL-12 or human sIL-4R, 0, 0, or 12.5% of them survived, respectively. However, 75% of these chimeras survived when they were treated with rIL-12 and sIL-4R in combination. These results indicate that HSV-1 infection in patient PBL-SCID chimeras was therapeutically controlled by the inducer of type 1 T cell responses and the inhibitor of type 2 T cell responses in combination.

Original languageEnglish (US)
Pages (from-to)363-370
Number of pages8
JournalClinical Immunology
Volume105
Issue number3
DOIs
StatePublished - Dec 1 2002

Fingerprint

Interleukin-4 Receptors
Severe Combined Immunodeficiency
Human Herpesvirus 1
Virus Diseases
Interleukin-12
Hot Temperature
Lymphocytes
T-Lymphocytes
Wounds and Injuries
Therapeutics
Survival
Antiviral Agents
Immunity
Tissue Donors
Cytokines
Infection

Keywords

  • HSV-1
  • IL-12
  • SCID chimera
  • sIL-4R
  • Thermally injured patients

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

A combination therapy using IL-12 and soluble IL-4 receptor on herpes simplex virus type 1 infection in a human-SCID chimera model of thermal injury. / Katakura, Tatsushi; Kobayashi, Makiko; Fujita, Kazuhiko; Herndon, David; Pollard, Richard B.; Suzuki, Fujio.

In: Clinical Immunology, Vol. 105, No. 3, 01.12.2002, p. 363-370.

Research output: Contribution to journalArticle

Katakura, Tatsushi ; Kobayashi, Makiko ; Fujita, Kazuhiko ; Herndon, David ; Pollard, Richard B. ; Suzuki, Fujio. / A combination therapy using IL-12 and soluble IL-4 receptor on herpes simplex virus type 1 infection in a human-SCID chimera model of thermal injury. In: Clinical Immunology. 2002 ; Vol. 105, No. 3. pp. 363-370.
@article{9e360ae0302d415290ceff3a714b3d60,
title = "A combination therapy using IL-12 and soluble IL-4 receptor on herpes simplex virus type 1 infection in a human-SCID chimera model of thermal injury",
abstract = "Herpes simplex virus type 1 (HSV-1) is a severe pathogen in thermally injured patients. Type 1 T cells are essential for the host's anti-HSV protective immunity. Type 2 cytokines, commonly detected in thermally injured patients, have been described as inhibitors for the type 1 T cell generation. Therefore, the antiviral effects of combination therapy with a type 1 T cell inducer [interleukin (IL)-12] and a type 2 T cell inhibitor [soluble IL-4 receptor (sIL-4R)] were investigated in severe combined immunodeficiency (SCID) mice inoculated with peripheral blood lymphocytes (PBL) of thermally injured patients. Patient PBL-SCID chimeras (SCID mice inoculated with patient PBL) were susceptible to infection with 1 × 103 PFU/kg of HSV-1 (0{\%} survival), while healthy PBL-SCID chimeras (SCID mice inoculated with PBL from healthy donors) were resistant (92{\%} survival). When patient PBL-SCID chimeras exposed to HSV-1 were treated with saline, human recombinant (r) IL-12 or human sIL-4R, 0, 0, or 12.5{\%} of them survived, respectively. However, 75{\%} of these chimeras survived when they were treated with rIL-12 and sIL-4R in combination. These results indicate that HSV-1 infection in patient PBL-SCID chimeras was therapeutically controlled by the inducer of type 1 T cell responses and the inhibitor of type 2 T cell responses in combination.",
keywords = "HSV-1, IL-12, SCID chimera, sIL-4R, Thermally injured patients",
author = "Tatsushi Katakura and Makiko Kobayashi and Kazuhiko Fujita and David Herndon and Pollard, {Richard B.} and Fujio Suzuki",
year = "2002",
month = "12",
day = "1",
doi = "10.1006/clim.2002.5300",
language = "English (US)",
volume = "105",
pages = "363--370",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A combination therapy using IL-12 and soluble IL-4 receptor on herpes simplex virus type 1 infection in a human-SCID chimera model of thermal injury

AU - Katakura, Tatsushi

AU - Kobayashi, Makiko

AU - Fujita, Kazuhiko

AU - Herndon, David

AU - Pollard, Richard B.

AU - Suzuki, Fujio

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Herpes simplex virus type 1 (HSV-1) is a severe pathogen in thermally injured patients. Type 1 T cells are essential for the host's anti-HSV protective immunity. Type 2 cytokines, commonly detected in thermally injured patients, have been described as inhibitors for the type 1 T cell generation. Therefore, the antiviral effects of combination therapy with a type 1 T cell inducer [interleukin (IL)-12] and a type 2 T cell inhibitor [soluble IL-4 receptor (sIL-4R)] were investigated in severe combined immunodeficiency (SCID) mice inoculated with peripheral blood lymphocytes (PBL) of thermally injured patients. Patient PBL-SCID chimeras (SCID mice inoculated with patient PBL) were susceptible to infection with 1 × 103 PFU/kg of HSV-1 (0% survival), while healthy PBL-SCID chimeras (SCID mice inoculated with PBL from healthy donors) were resistant (92% survival). When patient PBL-SCID chimeras exposed to HSV-1 were treated with saline, human recombinant (r) IL-12 or human sIL-4R, 0, 0, or 12.5% of them survived, respectively. However, 75% of these chimeras survived when they were treated with rIL-12 and sIL-4R in combination. These results indicate that HSV-1 infection in patient PBL-SCID chimeras was therapeutically controlled by the inducer of type 1 T cell responses and the inhibitor of type 2 T cell responses in combination.

AB - Herpes simplex virus type 1 (HSV-1) is a severe pathogen in thermally injured patients. Type 1 T cells are essential for the host's anti-HSV protective immunity. Type 2 cytokines, commonly detected in thermally injured patients, have been described as inhibitors for the type 1 T cell generation. Therefore, the antiviral effects of combination therapy with a type 1 T cell inducer [interleukin (IL)-12] and a type 2 T cell inhibitor [soluble IL-4 receptor (sIL-4R)] were investigated in severe combined immunodeficiency (SCID) mice inoculated with peripheral blood lymphocytes (PBL) of thermally injured patients. Patient PBL-SCID chimeras (SCID mice inoculated with patient PBL) were susceptible to infection with 1 × 103 PFU/kg of HSV-1 (0% survival), while healthy PBL-SCID chimeras (SCID mice inoculated with PBL from healthy donors) were resistant (92% survival). When patient PBL-SCID chimeras exposed to HSV-1 were treated with saline, human recombinant (r) IL-12 or human sIL-4R, 0, 0, or 12.5% of them survived, respectively. However, 75% of these chimeras survived when they were treated with rIL-12 and sIL-4R in combination. These results indicate that HSV-1 infection in patient PBL-SCID chimeras was therapeutically controlled by the inducer of type 1 T cell responses and the inhibitor of type 2 T cell responses in combination.

KW - HSV-1

KW - IL-12

KW - SCID chimera

KW - sIL-4R

KW - Thermally injured patients

UR - http://www.scopus.com/inward/record.url?scp=0036913593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036913593&partnerID=8YFLogxK

U2 - 10.1006/clim.2002.5300

DO - 10.1006/clim.2002.5300

M3 - Article

VL - 105

SP - 363

EP - 370

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -